MARCOS
GONZÁLEZ DÍAZ
Investigador en el periodo 1993-2023
Hospital Universitario La Fe
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario La Fe (37)
2023
-
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia
Blood Advances, Vol. 7, Núm. 1, pp. 167-173
2021
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
2020
-
Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
Experimental Hematology and Oncology
2018
-
Focal adhesion genes refine the intermediate-risk cytogenetic classification of acute myeloid leukemia
Cancers, Vol. 10, Núm. 11
-
Wilms Tumor 1 gene expression levels improve risk stratification in AML patients. Results of a multicentre study within the Spanish Group for Molecular Biology in Haematology
British Journal of Haematology
2017
-
NEDD 9 an independent good prognostic factor in intermediaterisk acute myeloid leukemia patients
Oncotarget, Vol. 8, Núm. 44, pp. 76003-76014
-
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia
Medicina Clinica, Vol. 148, Núm. 8, pp. 381.e1-381.e9
2016
-
Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
Oncotarget, Vol. 7, Núm. 49, pp. 80916-80924
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
2015
2014
-
Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry
Leukemia, Vol. 28, Núm. 2, pp. 391-397
-
Hairy cell leukemia treated initially with purine analogs: A retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC)
Leukemia and Lymphoma, Vol. 55, Núm. 5, pp. 1007-1012
2012
-
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen
Bone Marrow Transplantation, Vol. 47, Núm. 10, pp. 1287-1293
2011
-
Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens
Blood, Vol. 117, Núm. 6, pp. 1799-1805
-
Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy
Haematologica, Vol. 96, Núm. 10, pp. 1470-1477
2010
-
Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
Haematologica, Vol. 95, Núm. 3, pp. 424-431
-
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
Blood, Vol. 116, Núm. 25, pp. 5650-5659
-
Early intervention during imatinib therapy in patients with newly diagnosed chronic-phase chronic myeloid leukemia: A study of the Spanish PETHEMA group
Haematologica, Vol. 95, Núm. 8, pp. 1317-1324
2009
-
Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis
Haematologica, Vol. 94, Núm. 9, pp. 1242-1249
-
Differentiation syndrome in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline chemotherapy: Characteristics, outcome, and prognostic factors
Blood, Vol. 113, Núm. 4, pp. 775-783